Revenue segments as reported by the company.

Medical Devices

Specialty Pharmaceuticals

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Royalty expense

Amortization expense

Intangible asset impairment charges

Contingent consideration net expense (benefit)

Restructuring net charges (credits)

Litigation-related net charges (credits)

Gain on disposal of businesses and assets

Goodwill impairment charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Boston Scientific

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Rhythm and Neuro, Cardiovascular and MedSurg. The Rhythm and Neuro segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment consists of technologies for diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative and invasive technologies. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979, and is headquartered in Marlborough, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Boston Scientific reports solid Q4 performance and eyes global growth

Boston Scientific's Q4 performance was solid, with growth across regions and business units.
Challenges include potential sales growth hurdles in Q1 2023 and headwinds from tough comps and market adjustments.
Opportunities lie in continued momentum in key business units, successful product launches, and global growth prospects.
The company remains focused on sustaining growth, expanding margins, and delivering double-digit adjusted EPS growth.

Boston Scientific surpasses Q1 expectations, eyes growth through Farapulse

Boston Scientific's Q1 '23 earnings call showcased strong performance, with exceeding revenue expectations and solid organic sales growth. The company's strategic focus on high-growth M&A, resolving supply constraints for Farapulse, and capital allocation priorities position it well for future growth. Challenges include potential earnings dilutive deals and addressing free cash flow conversion challenges.

Boston Scientific surpasses Q2 expectations, eyes margin expansion and innovation

Boston Scientific delivered a strong Q2 '23 performance, exceeding expectations with robust sales growth and improved adjusted EPS, driven by strong performance across key regions and business segments.
While facing challenges such as inflation impact and market dynamics, the company remains focused on opportunities for margin expansion, product innovation, and strategic acquisitions to drive future growth.
With a positive outlook for the coronary business, upcoming product launches, and a commitment to operational excellence, Boston Scientific aims to maintain its competitive edge and capitalize on market opportunities.
Anticipated results from trials, market potential for new products, and a focus on sustainable growth strategies position Boston Scientific for continued success and market leadership in the healthcare sector.

Boston Scientific surpasses Q3 expectations, eyes growth opportunities ahead

Boston Scientific's Q3 2023 results exceeded expectations, with strong performance across regions and business units.
The company raised full-year guidance, expecting organic revenue growth of approximately 11% and adjusted EPS range of $1.99 to $2.02.
Challenges in the Neuromodulation business and cost impacts are being addressed for future improvement.
Opportunities lie in acquisitions, FDA approvals, and strategic commercial initiatives for growth and margin expansion.

Boston Scientific (BSX) exceeds Q4 expectations, eyes growth opportunities

Boston Scientific (BSX) reported impressive Q4 2023 results, exceeding sales and EPS guidance.
The company showcased strong regional growth, highlighted key products, and outlined solid 2024 outlook.
While facing challenges like delayed product launches and market disruptions, BSX remains focused on growth opportunities.
Strategic acquisitions and margin improvement initiatives position Boston Scientific for continued success in the future.

Boston Scientific beats Q1 expectations, eyes growth in key markets

Boston Scientific delivered strong Q1 results, exceeding expectations and showcasing growth across key regions and business units.
While facing challenges like inventory charges, the company is focused on leveraging opportunities in expanding product indications and enhancing capabilities.
With raised full-year guidance and a focus on innovation and market expansion, Boston Scientific is poised for continued growth and success in 2024.

Boston Scientific (BSX) reports stellar Q2 results and eyes sustained growth

Boston Scientific's Q2 2024 performance exceeded expectations, showcasing strong financial results and regional sales growth across key markets.
The company's strategic strengths lie in diversified business units, innovative products like FARAPULSE, and strategic acquisitions like Silk Road Medical.
While challenges exist in adoption metrics and margin expansion, BSX's focus on reinvestment and growth opportunities position it well for sustained success.

Boston Scientific surpasses Q3 expectations, eyes growth opportunities in Asia

Boston Scientific's Q3 performance exceeded expectations, driven by strong sales growth and increased adjusted EPS.
The company's focus on innovation and strategic investments in key business units like Cardiology and Neuromodulation bode well for future growth.
Despite challenges in China and the need to deliver on growth targets, Boston Scientific remains confident in its ability to sustain top-tier financial performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Per Boston Scientific's (BSX) October update, it has started to see strong region-wise recovery.

Boston Scientific (BSX) LOTUS Edge Recall to Mar Q4 Earnings

New York, New York--(Newsfile Corp. - January 26, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Boston Scientific Corporation (NYSE: BSX) ("Boston Scientific" or the "Company") from April 24, 2019 through November 16, 2020 (the "Class Period"). The...

BSX FILING DEADLINE IN 1 WEEK: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion In a Securities Class Action Lawsuit Against Boston Scientific Corporation

The latest FDA approval of Boston Scientific's (BSX) fourth-generation Vercise Genus DBS System is aimed at improving patients' quality of life.

Boston Scientific's (BSX) DBS System Gets FDA's Clearance

Costco

Intuitive Surgical

Amassing $1 million may be much more achievable than you think.

Investing in These Stocks Could Make You a Millionaire Retiree

NEW YORK, Jan. 25, 2021 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has filed a class action suit in the United States District Court for the District of Massachusetts against Boston Scientific Corporation ("Boston Scientific" or "BSX" or the "Company") (NYSE: BSX) and...

Kaplan Fox Has Filed a Class Action to Recover Losses for Investors Who Purchased Boston Scientific Corporation Securities

NEW YORK, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Boston Scientific Corporation (NYSE: BSX) between April 24, 2019 and November 16, 2020, inclusive (the "Class Period"), of the important February 2, 2021 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Boston Scientific investors under the federal securities laws.

ROSEN, TRUSTED INVESTOR COUNSEL, Reminds Boston Scientific Corporation Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses Exceeding $100K to Contact Firm – BSX

New York, New York--(Newsfile Corp. - January 23, 2021) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Boston Scientific Corporation (NYSE: BSX) between April 24, 2019 and November 16, 2020, inclusive (the "Class Period"), of the important February 2, 2021 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Boston Scientific investors under the federal securities laws.To join the Boston...

ROSEN, A TOP RANKED LAW FIRM, Reminds Boston Scientific Corporation Investors of Important February 2 Deadline in Securities Class Action; Encourages Investors with Losses Exceeding $100K to Contact Firm - BSX

Boston Scientific (NYSE: BSX) recently announced that it entered into a definitive agreement to buy Preventice Solutions for $925 million. These are the details.

Why Boston Scientific Is Buying Preventice Solutions For $925 Million

LOS ANGELES, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming February 2, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX ) securities between April 24, 2019 and November 16, 2020, inclusive (the “Class Period”).

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Boston Scientific Corporation (BSX)

Boston Scientific's (BSX) acquisition of Preventice solutions enables the former to expand rhythm management diagnostics portfolio and abilities.

Boston Scientific (BSX) Enhances Core Business With Buyout

MARLBOROUGH, Mass., Jan. 22, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval of its fourth-generation Vercise Genus™ Deep Brain Stimulation (DBS) System. The portfolio, approved for conditional use in a magnetic...

Boston Scientific Receives FDA Approval For The Vercise Genus™ Deep Brain Stimulation System

NEW YORK, Jan. 21, 2021 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Boston Scientific Corporation (NYSE: BSX) between April 24, 2019 and November 16, 2020, inclusive (the "Class Period"), of the important February 2, 2021 lead...

ROSEN, LEADING INVESTOR COUNSEL, Reminds Boston Scientific Corporation Investors of Important February 2 Deadline in Securities Class Action; Encourages Investors with Losses Exceeding $100K to Contact Firm - BSX

Boston Scientific Inc. said Thursday it has agreed to acquire privately held Preventice Solutions Inc. for an upfront payment of $925 million and up to $300 million in potential milestone payments. The company has been an investor in Preventice since 2015 and currently owns a 22% state.

Boston Scientific to acquire Preventice Solutions for $925million in cash, up to $300 million in potential milestone payments

MARLBOROUGH, Mass., Jan. 21, 2021 /PRNewswire/ -- Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire Preventice Solutions, Inc., a privately-held company which offers a full portfolio of mobile cardiac health solutions and services,...

Boston Scientific Announces Agreement To Acquire Preventice Solutions, Inc.

Baxter

Medtronic

Stryker

Thermo Fisher Scientific

The pandemic is only a temporary setback for this diversified global manufacturer of medical devices.

This Medical Device Maker Will Be Well Positioned Post COVID

New York, New York--(Newsfile Corp. - January 20, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX) and certain of its officers. The class action, filed in United States District Court for the Eastern District of New York, and docketed under 20-cv-05894, is on behalf of a class consisting of all persons other than Defendants who purchased or...

SHAREHOLDER ALERT; Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming Deadline - BSX

LOS ANGELES, Jan. 20, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX)...

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Boston Scientific Corporation (BSX) Investors

Kandi Technologies Group Inc

Minerva Neurosciences

NEW YORK, NY / ACCESSWIRE / January 17, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

SHAREHOLDER ALERT: BSX NERV KNDI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

MARLBOROUGH, Mass., Jan. 14, 2021 /PRNewswire/ -- Boston Scientific (NYSE: BSX) has announced a limited market release of the WaveWriter Alpha™ portfolio of Spinal Cord Stimulator (SCS) systems. The unified portfolio of four MRI conditional, Bluetooth-enabled rechargeable and...

Boston Scientific Launches WaveWriter Alpha™ Spinal Cord Stimulator Systems In U.S.

SolarWinds Corp

NEW YORK, NY / ACCESSWIRE / January 13, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit.

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of BSX, NERV and SWI

BENSALEM, Pa., Jan. 13, 2021 /PRNewswire/ -- Law Offices of Howard G. Smith reminds investors of the upcoming February 2, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Boston Scientific Corporation ("Boston Scientific" or the...

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Boston Scientific Corporation (BSX)

We think that Baxter International currently is a better pick compared to Boston Scientific. BAX stock trades at about 3.6x trailing Revenues, compared to around 5.2x for Boston Scientific.

Baxter Is A Better Choice Than Boston Scientific Stock

BOSTON, Jan. 12, 2021 /PRNewswire/ -- The Greater New England Minority Supplier Development Council (GNEMSDC) has received an investment of $50,000 from Boston Scientific Corporation, a global medical technology leader. In collaboration with a team of specialists from Boston Scientific,...

Boston Scientific Invests in Greater New England Minority Supplier Development Council's (GNEMSDC) Development Program for Minority Owned Businesses

Shares of Boston Scientific Corp. sank 4.2% in premarket trading Tuesday, after the medical technology company provided a fourth-quarter sales outlook that was below Wall Street forecasts. The company expects to report sales for the quarter to Dec. 31 of $2.71 billion, down 6.8% from a year ago and below the FactSet consensus of $2.86 billion.

Boston Scientific's stock sinks after downbeat sales outlook

MARLBOROUGH, Mass., Jan. 12, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales, based upon preliminary unaudited financial information, of approximately $2.71 billion during the fourth quarter of 2020. This represents a decline of approximately (6.8)...

News for Boston Scientific Stock (BSX)